Expanse ICE has announced the FDA clearance for its ICE Aspiration System. 

This development marks a key milestone in the field of peripheral thrombectomy, introducing a promising new player to address the challenges associated with this critical medical procedure.

Peripheral thrombectomy, aimed at treating blood clots, is a vital intervention in vascular medicine, given that blood clots rank as the third most common vascular disease. With nearly one million patients requiring treatment for peripheral blood clots annually, and up to 33 percent experiencing long-term complications, according to the Center for Disease Control, the demand for effective solutions is evident.

Dr. Eitan Konstantino, a respected figure in the vascular device field and the driving force behind Expanse ICE, expressed enthusiasm for the ICE System's unique design. "We've engineered the ICE catheter system to harness the aspiration power typical of a large bore catheter, but within the slender profile of a much smaller device," Dr. Konstantino remarked, highlighting the innovative approach taken by the Expanse ICE team.

Medical professionals worldwide have eagerly anticipated the launch of the ICE Aspiration System, recognizing its potential to address critical challenges in peripheral thrombectomies. Dr. Michael Lichtenberg, Chief Medical Officer of Angiology at the Vascular Center Clinic in Arnsberg, Germany, commended the device's design, stating, "It is clear this device was built with physicians in mind." Dr. Lichtenberg's endorsement highlights the device's intuitive design and its potential to enhance patient care.

Similarly, Dr. Aravinda Nanjundappa, Director of Peripheral Vascular Interventions at the Cleveland Clinic, expressed keen interest in adopting the Expanse ICE system. "Its ability to offer powerful clot removal in a compact size is an intriguing proposition that could significantly enhance our ability to meet patient needs more effectively and improve treatment outcomes in peripheral vascular disease," Dr. Nanjundappa remarked, highlighting the potential impact of the ICE Aspiration System on clinical practice.

Industry experts have also taken note of the ICE System's arrival in the thrombectomy market. Shlomi Nachman, former Johnson & Johnson Company Group Chairman of Cardiovascular and Specialty Solutions and Vision, commented on the significance of this development, stating, "The thrombectomy market is witnessing robust growth, and the approval of the ICE system comes at an auspicious time." Nachman's remarks underline the industry's recognition of the ICE System as cutting-edge technology poised to make a substantial impact in an underpenetrated market.